Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADAGIO-3 Long-term Safety and Tolerability of KarXT + KarX-EC in Agitation Associated with Alzheimer's Disease
jRCT2031250672Phase 3Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2026
- Modality
- Small Molecules
01
Overview
Phase 3, open-label, single-arm trial of xanomeline and KarX-EC in Alzheimer's disease (AD), sponsored by Bristol Myers Squibb. Primary endpoint: Incidence of any TEAEs. Started Jan 2026; status: recruiting.
02
Drugs
xanomelineKarX-EC
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on jRCT2031250672.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250672.